Related Experiment Video

Updated: May 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Moving toward personalized medicine in castration-resistant prostate cancer

Eliezer M Van Allen1, Mark Pomerantz

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

The Urologic Clinics of North America
|October 23, 2012
PubMed

Insights

Molecular characterization advances personalized medicine for castration-resistant prostate cancer (CRPC). Treatments now target individual tumor profiles, focusing on hormone resistance and immune pathways for tailored therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Castration-resistant prostate cancer (CRPC) presents significant treatment challenges.
  • Advances in research technology enable detailed molecular profiling of CRPC.
  • Understanding tumor-specific alterations is key to developing effective therapies.

Purpose of the Study:

  • To highlight how molecular characterization is revolutionizing CRPC treatment.
  • To discuss potential therapeutic targets unique to individual prostate cancer profiles.
  • To illustrate the shift towards personalized medicine in CRPC management.

Main Methods:

  • Utilizing advanced research technologies for molecular characterization of CRPC.
  • Identifying key molecular targets including the androgen receptor pathway and immune system components.
  • Analyzing individual patient tumor profiles to guide treatment selection.

Main Results:

  • Improved molecular understanding of CRPC heterogeneity.
  • Identification of specific targets for personalized therapeutic strategies.
  • Demonstration of the feasibility of tailoring treatments based on tumor molecular data.

Conclusions:

  • Personalized medicine approaches are transforming CRPC treatment.
  • Targeting specific molecular alterations offers a promising future for CRPC management.
  • CRPC treatment is evolving into a prime example of precision oncology.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...